Zacks Research Has Bullish Forecast for AGIO FY2026 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Stock analysts at Zacks Research increased their FY2026 earnings estimates for Agios Pharmaceuticals in a research note issued on Thursday, September 17th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn ($6.93) per share for the year, up from their previous estimate of ($6.94). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.82) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.76) EPS, Q1 2027 earnings at ($1.59) EPS, Q2 2027 earnings at ($1.60) EPS, Q3 2027 earnings at ($1.49) EPS, Q4 2027 earnings at ($1.42) EPS, FY2027 earnings at ($6.11) EPS, Q1 2028 earnings at ($1.21) EPS, Q2 2028 earnings at ($1.01) EPS and FY2028 earnings at ($3.70) EPS.

A number of other brokerages also recently issued reports on AGIO. Citigroup increased their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. TD Cowen raised Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. HC Wainwright upped their target price on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Royal Bank Of Canada increased their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. Finally, Bank of America raised their price target on Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $41.75.

Agios Pharmaceuticals Trading Up 3.0%

Shares of AGIO opened at $34.97 on Monday. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00. The firm’s 50 day moving average is $34.18 and its 200-day moving average is $32.24. The stock has a market capitalization of $2.09 billion, a PE ratio of -4.99 and a beta of 0.60.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The business had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million.

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Nykredit A S acquired a new position in Agios Pharmaceuticals during the 2nd quarter valued at about $26,000. Quantinno Capital Management LP increased its holdings in Agios Pharmaceuticals by 2.7% during the 1st quarter. Quantinno Capital Management LP now owns 27,591 shares of the biopharmaceutical company’s stock worth $933,000 after purchasing an additional 736 shares in the last quarter. AlphaCentric Advisors LLC raised its stake in shares of Agios Pharmaceuticals by 6.3% in the first quarter. AlphaCentric Advisors LLC now owns 13,971 shares of the biopharmaceutical company’s stock worth $473,000 after purchasing an additional 830 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Agios Pharmaceuticals by 10.0% in the fourth quarter. ProShare Advisors LLC now owns 12,897 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 1,169 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $43,000.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at $1,665,579.60. This trade represents a 35.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by company insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases, with an emphasis on disorders involving cellular metabolism. The company’s research has centered on small-molecule therapies designed to address underlying biological mechanisms rather than only treating symptoms.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase approved in the United States and other markets for the treatment of hemolytic anemia associated with pyruvate kinase deficiency in adults.